Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 10/2018

Open Access 01-10-2018 | Original Paper

Prevalence, Comorbidity, and Correlates of Psychiatric and Substance Use Disorders and Associations with HIV Risk Behaviors in a Multisite Cohort of Women Living with HIV

Authors: Judith A. Cook, Jane K. Burke-Miller, Pamela J. Steigman, Rebecca M. Schwartz, Nancy A. Hessol, Joel Milam, Daniel J. Merenstein, Kathryn Anastos, Elizabeth T. Golub, Mardge H. Cohen

Published in: AIDS and Behavior | Issue 10/2018

Login to get access

Abstract

We used the World Health Organization’s Composite International Diagnostic Interview to determine the prevalence, comorbidity, and correlates of lifetime and 12-month behavioral health disorders in a multisite cohort of 1027 women living with HIV in the United States. Most (82.6%) had one or more lifetime disorders including 34.2% with mood disorders, 61.6% with anxiety disorders, and 58.3% with substance use disorders. Over half (53.9%) had at least one 12-month disorder, including 22.1% with mood disorders, 45.4% with anxiety disorders, and 11.1% with substance use disorders. Behavioral health disorder onset preceded HIV diagnosis by an average of 19 years. In multivariable models, likelihood of disorders was associated with women’s race/ethnicity, employment status, and income. Women with 12-month behavioral health disorders were significantly more likely than their counterparts to engage in subsequent sexual and substance use HIV risk behaviors. We discuss the complex physical and behavioral health needs of women living with HIV.
Literature
1.
Arendt G. Affective disorders in patients with HIV infection. CNS Drug Rev. 2006;20(6):507–18.CrossRef
2.
Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients. Drugs. 2006;66(6):769–89.CrossRef
3.
Klinkenberg WD, Sacks S. The HIV/AIDS treatment adherence, health outcomes and cost study group. Mental disorders and drug abuse in persons living with HIV/AIDS. AIDS Care. 2004;16(sup1):22–42.CrossRef
4.
Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. New Engl J Med. 1998;339(26):1897–904.CrossRef
5.
Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus–infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRef
6.
Orlando M, Burnam MA, Beckman R, Morton SC, London AS, Bing EG, Fleishman JA. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV cost and services utilization study. Int J Method Psychiatr. 2002;11(2):75–82.CrossRef
7.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.CrossRef
8.
Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–27.CrossRef
9.
Gala C, Pergami A, Catalan J, et al. The psychosocial impact of HIV infection in gay men, drug users and heterosexuals. Controlled investigation. Br J Psychiatry. 1993;163(5):651–9.CrossRef
10.
Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505–11.CrossRef
11.
Lyketsos CG, Hanson A, Fishman M, McHugh PR, Treisman GJ. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatr Med. 1994;24(2):103–13.CrossRef
12.
Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDs. 2008;22(3):233–43.CrossRef
13.
Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United States. J Acquir Immune Defic Syndr. 2006;42(3):298–306.CrossRef
14.
Rabkin JG. Prevalence of psychiatric disorders in HIV illness. Int Rev Psychiatry. 1996;8:157–66.CrossRef
15.
Dew MA, Reynolds CF, Houck PR, et al. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry. 1997;54(11):1016–24.CrossRef
16.
Dausey DJ, Desai RA. Psychiatric comorbidity and the prevalence of HIV infection in a sample of patients in treatment for substance abuse. J Nerv Ment Dis. 2003;191(1):10–7.CrossRef
17.
DeLorenze GN, Tsai AL, Horberg MA, Quesenberry CP. Cost of care for HIV-infected patients with co-occurring substance use disorder or psychiatric disease: report from a large, integrated health plan. AIDS Res Treat. 2014;24:1–9.
18.
Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry. 2001;58(8):729–36.CrossRef
19.
Galvan FH, Burnam MA, Bing EG. Co-occurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people. J Psychoact Drugs. 2003;35(sup1):153–60.CrossRef
20.
DeLorenze GN, Satre DD, Quesenberry CP Jr, Tsai AL, Weisner CM. Mortality after diagnosis of psychiatric disorders and co-occurring substance use disorders among HIV-infected patients. AIDS Patient Care STDs. 2010;24(11):705–12.CrossRef
21.
Malee K, Mellins CA, Huo Y, et al. Prevalence, incidence and persistence of psychiatric and substance use disorders among mothers living with HIV. J Acquir Immune Defic Syndr. 2014;65(5):526–34.CrossRef
22.
Parhami I, Fong TW, Siani A, Carlotti C, Khanlou H. Documentation of psychiatric disorders and related factors in a large sample population of HIV-positive patients in California. AIDS Behav. 2013;17:2792–801.CrossRef
23.
Cook JA, Grey DD, Burke-Miller JK, et al. Illicit drug use, depression and their association with highly active antiretroviral therapy in HIV-positive women. Drug Alcohol Depend. 2007;89(1):74–81.CrossRef
24.
Cook RL, Zhu F, Belnap BH, et al. Longitudinal trends in hazardous alcohol consumption among women with human immunodeficiency virus infection, 1995–2006. Am J Epidemiol. 2009;169(8):1025–32.CrossRef
25.
Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and mortality in a multi-center cohort of HIV-1 positive women. AIDS. 2008;22(11):1355–63.CrossRef
26.
Edwards A. Recognizing the influence of social determinants on HIV risk behaviors and the need for structural interventions to prevent HIV in women. J Health Dispar Res Pract. 2015;7(7):10–25.
27.
Sharpe TT, Voûte C, Rose MA, Cleveland J, Dean HD, Fenton K. Social determinants HIV/AIDS and sexually transmitted diseases among black women: implications for health equity. J Womens Health. 2012;21(3):249–54.CrossRef
28.
Cook JA, Burke-Miller JK, Grey DD, Coccohoba J, Liu C, Schwartz R, Golub ET, Anastos K, Steigman PJ, Cohen MH. Do HIV-positive women receive depression treatment that meets best practice guidelines? AIDS Behav. 2014;18(6):1094–102.CrossRef
29.
Otto-Salaj LL, Kelly JA, Stevenson LY, Hoffmann R, Kalichman SC. Outcomes of a randomized small-group HIV prevention intervention trial for people with serious mental illness. Community Ment Health J. 2001;37(2):123–44.CrossRef
30.
Santelli JS, Robin L, Brener ND, Lowry R. Timing of alcohol and other drug use and sexual risk behaviors among unmarried adolescents and young adults. Fam Plann Perspect. 2001;33:200–5.CrossRef
31.
Metsch LR, McCoy CB, Lai S, Miles C. Continuing risk behaviors among HIV-seropositive chronic drug users in Miami, Florida. AIDS Behav. 1998;2(2):161–9.CrossRef
32.
Brewer TH, Zhao W, Metsch LR, Coltes A, Zenilman J. High-risk behaviors in women who use crack: knowledge of HIV serostatus and risk behavior. Ann Epidemiol. 2007;17(7):533–9.CrossRef
33.
Hutton HE, Lyketsos CG, Zenilman JM, Thompson RE, Erbelding EJ. Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. Am J Psychiatry. 2004;161(5):912–4.CrossRef
34.
Staton-Tindall M, Harp KL, Minieri A, et al. An exploratory study of mental health and HIV risk behavior among drug-using rural women in jail. Psychiatr Rehabil J. 2015;38(1):45–54.CrossRef
35.
Campsmith ML, Nakashima AK, Jones JL. Association between crack cocaine use and high-risk sexual behaviors after HIV diagnosis. J Acquir Immune Defic Syndr. 2000;25(2):192–8.CrossRef
36.
Newville H, Haller DL. Psychopathology and transmission risk behaviors in patients with HIV/AIDS. AIDS Care. 2010;22(10):1259–68.CrossRef
37.
Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry. 2003;160(9):1659–62.CrossRef
38.
Miles DR, Svikis DS, Kulstad JL, Haug NA. Psychopathology in pregnant drug-dependent women with and without comorbid alcohol dependence. Alcohol Clin Exp Res. 2001;25(7):1012–7.CrossRef
39.
Mota NP, Cox BJ, Katz LY, Sareen J. Relationship between mental disorders/suicidality and three sexual behaviors: results from the National Comorbidity Survey Replication. Arch Sex Behav. 2010;39(3):724–34.CrossRef
40.
Plotzker RE, Metzger DS, Holmes WC. Childhood sexual and physical abuse histories, PTSD, depression, and HIV risk outcomes in women injection drug users: a potential mediating pathway. Am J Addict. 2007;16(6):431–8.CrossRef
41.
Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446–53.CrossRef
42.
Latka MH, Wilson TE, Cook JA, Bacon MC, Richardson JL, Sohler N, Cohen MH, Greenblatt RM, Andreopoulis E, Vlahov D. Impact of drug treatment on subsequent sexual risk behavior in a multisite cohort of drug-using women: a report from the Women’s Interagency HIV Study. J Subst Abuse Treat. 2005;29(4):329–37.CrossRef
43.
Crepaz N, Marks G, Liau A, Mullins MM, Aupont LW, Marshall KJ, Jacobs ED, Wolitski RJ. HIV/AIDS Prevention Research Synthesis (PRS) Team. Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis. AIDS. 2009;23(13):1617–29.CrossRef
44.
Meade CS, Kershaw TS, Hansen NB, Sikkema KJ. Long-term correlates of childhood abuse among adults with severe mental illness: adult victimization, substance abuse, and HIV sexual risk behavior. AIDS Behav. 2009;13(2):207–16.CrossRef
45.
Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J. The women’s interagency HIV study. Epidemiology. 1998;9(2):117–25.CrossRef
46.
Bacon MC, von Wyl V, Alden C, et al. The Women’s Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12(9):1013–9.PubMedPubMedCentral
47.
Kessler RC, Üstün TB. The world mental health (WMH) survey initiative version of the world health organization (WHO) composite international diagnostic interview (CIDI). Int J Methods Psychiatr Res. 2004;13(2):93–121.CrossRef
48.
US Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med. 2004;140(7):554–6.CrossRef
49.
Alegría M, Jackson JS, Kessler RC, Takeuchi D. Collaborative Psychiatric Epidemiology Surveys (CPES), 2001–2003 [United States]. ICPSR20240-v8. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor]. 2015;2015-12-09. http://​doi.​org/​10.​3886/​ICPSR20240.​v8.
50.
Back SE, Brady KT. Anxiety disorders with comorbid substance use disorders: diagnostic and treatment considerations. Psychiatr Ann. 2008;38(11):724–9.CrossRef
51.
Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807–16.CrossRef
52.
Pettinati HM, O’Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23–30.CrossRef
53.
54.
Cook JA, Burke-Miller JK, Roessel E. Long-term effects of evidence-based supported employment on earnings and on SSI and SSDI participation among individuals with psychiatric disabilities. Am J Psychiatry. 2016;173(10):1007–14.CrossRef
55.
Reddy LF, Junghee L, Davis MC, Altschuler L, et al. Impulsivity and risk taking in bipolar disorder and schizophrenia. Neuropsychopharmacology. 2014;39:456–63.CrossRef
56.
Desrichard O, Denarie V. Sensation seeking and negative affectivity as predictors of risky behaviors: a distinction between occasional versus frequent risk-taking. Addict Behav. 2005;30(7):1449–53.CrossRef
57.
Abramawitz JS, Whiteside S, Lynam D, Kalsy S. Is thought-action fusion specific to obsessive-compulsive disorder?: a medicating role of negative affect. Behav Res Ther. 2003;41(9):1069–79.CrossRef
58.
Cournos F, McKinnon K, Wainberg M. What can mental health interventions contribute to the global struggle against HIV/AIDS. World Psychiatry. 2005;4(3):135–41.PubMedPubMedCentral
59.
Pence BW. The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. J Antimicrob Chemother. 2009;63(4):636–40.CrossRef
60.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.CrossRef
61.
Nair P, Schuler ME, Black MM, Kettinger L, Harrington D. Cumulative environmental risk in substance abusing women: early intervention, parenting stress, child abuse potential and child development. Child Abuse Negl. 2003;27(9):997–1017.CrossRef
62.
Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine JP. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276(4):293–9.CrossRef
63.
Alegria M, Jackson JS, Kessler RC, Takeuchi D. Collaborative Psychiatric Epidemiology Surveys (CPES), 2001–2003 [United States]. ICPSR20240-v6. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor]. 2008:06–19.
64.
Delgado PL, Alegría M, Cañive JM, et al. Depression and access to treatment among US Hispanics: review of the literature and recommendations for policy and research. Focus. 2006;4(1):38–47.CrossRef
65.
Johnson SD, Cunningham-Williams RM, Cottler LB. A tripartite of HIV-risk for African American women: the intersection of drug use, violence, and depression. Drug Alcohol Depend. 2003;70(2):169–75.CrossRef
66.
Weiss JJ, Morgello S. Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. Gen Hosp Psychiatry. 2009;31(6):531–7.CrossRef
67.
Grembowski D, Schaefer J, Johnson KE, Fischer H, Moore SL, Tai-Seale M, Ricciardi R, Fraser JR, Miller D, LeRoy L. A conceptual model of the role of complexity in the care of patients with multiple chronic conditions. Med Care. 2014;52:S7–14.CrossRef
68.
Kathol RG, Knutson KH, Dehnel PJ. Health Complexity and the Interaction Between Physical and Behavioral Health Conditions in Children and Youth. In Physician’s Guide 2016 (pp. 51–77). Springer International Publishing.
69.
McHugh RK. Treatment of co-occurring anxiety disorders and substance use disorders. Harv Rev Psychiatry. 2015;23(2):99–111.CrossRef
70.
Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167(6):668–75.CrossRef
71.
Hien DA, Wells EA, Jiang H, et al. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol. 2009;77(4):607–19.CrossRef
72.
Katon W, Von Korff M, Lin E, Simon G. Rethinking practitioner roles in chronic illness: the specialist, primary care physician, and the practice nurse. Gen Hosp Psychiatry. 2001;23(3):138–44.CrossRef
73.
74.
Cheever LW, Kresina TF, Cajina A, Lubran R. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J Acquir Immune Defic Syndr. 2011;56:S3–6.CrossRef
75.
Curran GM, Pyne J, Fortney JC, et al. Development and implementation of collaborative care for depression in HIV clinics. AIDS Care. 2011;23(12):1626–36.CrossRef
76.
Ojikutu B, Holman J, Kunches L, et al. Interdisciplinary HIV care in a changing healthcare environment in the USA. AIDS Care. 2014;26(6):731–5.CrossRef
77.
Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR* D study: treating depression in the real world. Cleve Clin J Med. 2008;75:57–66.CrossRef
78.
Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;7(2):99–105.CrossRef
Metadata
Title
Prevalence, Comorbidity, and Correlates of Psychiatric and Substance Use Disorders and Associations with HIV Risk Behaviors in a Multisite Cohort of Women Living with HIV
Authors
Judith A. Cook
Jane K. Burke-Miller
Pamela J. Steigman
Rebecca M. Schwartz
Nancy A. Hessol
Joel Milam
Daniel J. Merenstein
Kathryn Anastos
Elizabeth T. Golub
Mardge H. Cohen
Publication date
01-10-2018
Publisher
Springer US
Published in
AIDS and Behavior / Issue 10/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2051-3

Other articles of this Issue 10/2018

AIDS and Behavior 10/2018 Go to the issue

Original Paper

Preferences for Sexual Health Smartphone App Features Among Gay and Bisexual Men

Substantive Review

AIDS-Affected Orphans in Sub-Saharan Africa: A Scoping Review on Outcome Differences in Rural and Urban Environments

Original Paper

Adapting the Risk Environment Framework to Understand Substance Use, Gender-Based Violence, and HIV Risk Behaviors Among Female Sex Workers in Tanzania

Original Paper

Mobile Health Technology for Improving Symptom Management in Low Income Persons Living with HIV

Original Paper

Empowering Lay-Counsellors with Technology: Masivukeni, a Standardized Multimedia Counselling Support Tool to Deliver ART Counselling

Original Paper

Intimate Partner Violence and HIV Sexual Risk Behaviour Among Women Who Inject Drugs in Indonesia: A Respondent-Driven Sampling Study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits